House Rx is a technology company.
House Rx has raised $55.0M across 1 funding round.
House Rx has raised $55.0M in total across 1 funding round.
House Rx has raised $55.0M in total across 1 funding round.
House Rx's investors include AlleyCorp, Andreessen Horowitz, CVS Health, Echo Health Ventures, Town Hall Ventures, Vivek Garipalli.
House Rx is a technology-enabled pharmacy services company founded in 2021 in San Francisco, California, that builds a platform and service to enable clinics to dispense specialty medications directly to patients.[1][2] It serves independent community practices and integrated health systems, solving key problems in the specialty pharmacy market—such as long fill times (industry average 15.5 days vs. House Rx's 3.5 days), high costs, and fragmented care—by fostering medically integrated dispensing where physicians and pharmacists collaborate via AI-powered tools for prior authorizations, scripting, and patient support.[1][2][4] The company has achieved strong growth momentum, partnering with over 1,000 providers at 80 clinic sites nationwide, processing more than $1.2 billion in specialty scripts for nearly 61,000 patients, and raising over $40 million initially, followed by a $55 million Series B in equity and debt to scale operations.[1][3][5]
House Rx was founded in 2021 by co-founder and CEO Ogi Kavazovic and a team with deep backgrounds in healthcare and technology, driven by frustration with a "broken" specialty pharmacy market where patients with complex conditions face delays and barriers to medication access.[1][2] The idea emerged from recognizing the need for a local, trusted, patient-centric model that integrates pharmacy services directly into clinics, allowing care teams to deliver combined medical and pharmacy care more efficiently.[2][4] Early traction came quickly through partnerships with specialty clinics like Marin Cancer Care and NWMS, where implementations reduced administrative burdens, sped up medication access, and improved patient outcomes—such as securing 80% copay reductions for patients like Larry switching from mail-order pharmacies.[1][4] Pivotal moments include debuting AI tools at the 2025 Community Oncology Conference and hitting key milestones like $1.2B in processed scripts.[1]
House Rx stands out in specialty pharmacy through:
House Rx rides the wave of AI-driven healthcare integration and the shift toward value-based care, where fragmented specialty pharmacy models (dominated by mail-order giants) fail patients with high-cost, complex drugs like those for cancer or autoimmune diseases.[1][2] Timing is ideal amid rising drug prices, regulatory pushes for faster access, and post-pandemic demand for localized care, amplified by AI advancements in automation—positioning House Rx to capture a slice of the $200B+ U.S. specialty pharmacy market.[1] Market forces like clinic revenue pressures and payer incentives for outcomes favor its MID model, influencing the ecosystem by empowering community practices to compete with big systems, standardizing tech-enabled dispensing, and setting benchmarks for patient affordability and speed.[4]
House Rx is primed to expand its AI platform beyond authorizations into full workflow automation (e.g., scheduling and analytics), targeting more oncology and specialty clinics while scaling to thousands of sites with fresh Series B capital.[1][3][5] Trends like AI proliferation in pharma, copay cap laws, and decentralized care will accelerate growth, potentially doubling script volume amid ecosystem shifts toward integrated models. Its influence could evolve from niche disruptor to category leader, redefining specialty pharmacy as clinic-native and patient-first—echoing its founding mission to break barriers for those who need it most.[2]
House Rx has raised $55.0M across 1 funding round. Most recently, it raised $55.0M Series B in November 2025.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Nov 1, 2025 | $55.0M Series B | AlleyCorp, Andreessen Horowitz, CVS Health, Echo Health Ventures, Town Hall Ventures, Vivek Garipalli |